A North American study of 52 infants with colic shows that babies given
Lactobacillus reuteri Protectis cry and fuss less compared to babies given
placebo.
The newly published study is the fourth positive colic study with Lactobacillus
reuteri Protectis and the results confirm the positive results of earlier
studies.
“Infantile colic is one of the major concerns of many parents of babies, and for
a long time, doctors and parents alike have struggled with a lack of treatment
options to ease colic symptoms in early infancy,” says Gideon Koren, Professor
at the University of Toronto and Senior Scientist at The Hospital for Sick
Children, Toronto, Canada, where the study was carried out. “It is critical to
evaluate probiotics with the same scientific rigour used for medicinal drugs.
Using these rigorous methods, we have shown that this probiotic can help
infants.”
Less crying already after a week
After seven days of treatment crying and fussing was reduced by more than 40
minutes per day in infants given Lactobacillus reuteri Protectis, whereas there
was practically no reduction in the placebo group. Crying and fussing continued
to decrease significantly in the Lactobacillus reuteri Protectis group
throughout the 21-day long study period. In the placebo group this decrease was
significantly smaller.
The study was published in the prestigious Journal of
Pediatrics (http://www.jpeds.com/webfiles/images/journals/ympd/ChauKoren.pdf) 24
October 2014. More information on
colic (http://www.biogaia.com/sites/biogaia.com/files/Press-material
-BioGaia_131030.pdf), study
details (http://www.biogaia.com/sites/biogaia.com/files/Study_details_Koren_2014
.
pdf) and previous colic studies with Lactobacillus reuteri
Protectis (http://www.biogaia.com/clinical
-studies?field_bg_indication_tid=182&age=All&author=All) is found through the
attached links.
"With this study – the fourth independent, positive study with Lactobacillus
reuteri Protectis on colic – we further strengthen our position in the
paediatric field. Furthermore, it is valuable that we now also have strong data
in this field from a study conducted in North America”, says Peter Rothschild,
President, BioGaia.
Latest press releases from BioGaia
2014-10-22 BioGaia AB Interim management report 1 January – 30 September 2014
2014-08-20 BioGaia AB Interim management report 1 January – 30 June 2014
2014-06-26 BioGaia expands in Eslöv
BioGaia has published this information in accordance with the Swedish Securities
Market Act. The information was issued for publication on 24 October 2014, 09:00
am CET.
For additional information please contact
Peter Rothschild, Chief Executive Officer, BioGaia: 46 8 555 293 00
BioGaia is a healthcare company that develops, markets and sells probiotic
products with documented health benefits. The products are primarily based on
the lactic acid bacterium Lactobacillus reuteri, which has probiotic, health
-enhancing effects. The class B share of the Parent Company BioGaia AB is quoted
on the Mid Cap list of the NASDAQ OMX Nordic Exchange Stockholm. www.biogaia.com
